A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Sponsor: Allergan
Terminated
The Relamorelin program is being terminated solely based on a business decision.
Other terminated trials from Allergan
Other Diabetes Mellitus trials with similar outcome
A PHASE3 clinical study on Diabetes Mellitus and Gastroparesis, this trial is terminated or withdrawn. The trial is conducted by Allergan and has accumulated 21 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
21 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 16 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Sep 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — Jun 2020 [monthly]
Recruiting PHASE3
-
Dec 2019 — Apr 2020 [monthly]
Recruiting PHASE3
-
Mar 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Sep 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
Status: Enrolling By Invitation → Recruiting
-
May 2018 — Jun 2018 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2018 — May 2018 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2018 — Feb 2018 [monthly]
Enrolling By Invitation PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .